System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Philipp B Staber

Hematology — Comprehensive Cancer Center Vienna, Austria

LeadR Profile

Philipp B Staber Comprehensive Cancer Center Vienna Austria
1 005 ScienceLeadR Reputation 1005

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 188

Citations

Citations: 5 287 1st author: 19 Last author: 22 Unique author: 3

Main journals

Blood 58
Leukemia 6
Hematol Oncol 5
J Clin Oncol 5
Blood Adv 4

Best Journals

J Clin Oncol 3
Lancet Oncol 2
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Ablation of CDK6 and STAT5B rewires T cell developmental dynamics and prevents ALK + lymphoma formation.
thymocytes, cells, lymphoma, neoplasms, t-lymphocytes		Nat Commun20260
Rare But Specific B-Cell Receptor Reactivity Against Coxsackievirus A24 in Primary Central Nervous System Lymphomas.
cells, antigens, viral, lymphoma, neoplasms, central nervous system, nervous system, b-lymphocytes, neurabins		EJHaem20260
Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.
hematology, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, lymph, therapeutics, telomere		Blood20260
Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.
lymphoma, macrophages, lymphoma, large b-cell, diffuse, therapeutics		Blood Neoplasia20260
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.
cells, hematology, lymphoma, b-cell, lymphoma, b-lymphocytes		Br J Haematol20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 12
Phase 2 6
N/A 2

By status:

Completed 10
Recruiting 7
Active not recruiting 1
Not yet recruiting 1
Terminated 1

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 17

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Randomized Open label Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R miniCHOP) in Older Adults with Untreated Diffuse Large B Cell Lymphoma (ARCHED GLA 2022 1)
2022-501187-18-00 — genes, myc, cells, lymphoma, follicular, hodgkin disease, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, herpesvirus 4, human, rituximab, histiocytes, t-lymphocytes, b-lymphocytes		Phase 3Recruiting2023
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca R) vs Investigator s Choice in Participants with Relapsed Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy
2024-519152-82-00 — lymphoma, follicular, safety, lymphoma, rituximab, therapeutics		Phase 3Recruiting2025
A phase 3 multicenter randomised prospective open label trial of fixed duration (12 cycles) venetoclax obinutuzumab vs fixed duration (15 cycles) venetoclax pirtobrutinib vs MRD guided venetoclax pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18 MOIRAI)
2023-510294-34-00 — research design, lymphoma, leukemia, lymphocytic, chronic, b-cell, duration of therapy, leukemia, leukemia, lymphoid, therapeutics, random allocation		Phase 3Recruiting2025
A PROSPECTIVE OPEN LABEL MULTICENTER RANDOMIZED PHASE 3 TRIAL OF ACALABRUTINIB OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
2023-506414-46-00 — leukemia, lymphocytic, chronic, b-cell, metaphase, leukemia, leukemia, lymphoid, chromosome aberrations, risk factors, therapeutics, karyotype, mutation		Phase 3Not yet recruiting2022
A Study of BGB 16673 Compared to Investigator s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
2024-518893-15-00 — lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, rituximab, retreatment		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS